**DRUG:** OSELTAMIVIR  

**PRESENTATION:** Capsules: 75mg  
Oral suspension 6 mg/mL  

**ACTION & INDICATION:** Antiviral for:  
Treatment of Influenza A, B, H1N1 (human swine influenza)  

**DOSE:**  
**Treatment Dose**  
<38 weeks 1 mg/kg/dose twice daily for 5 days  
38-40 weeks 1.5 mg/kg/dose twice daily for 5 days  
>40 weeks 3 mg/kg/dose twice daily for 5 days  
A longer duration of therapy may be considered for patients who remain severely ill after 5 days of treatment.  

**PREPARATION:**  
Add 55 mL of water to powder for suspension in the bottle = 6mg/mL  
If commercial oral suspension not available or not suitable, (see Comments) dose can be prepared by dispersing the contents of one 75mg capsule with 6.25mL of water = 12mg/mL. Allow 2 minutes to disperse.  

**ADMINISTRATION:**  
Oral: May be given with or without food. Tolerability may be improved with food  
To avoid confusion, the supplied Tamiflu® oral syringe should not be used.  

**ADVERSE EFFECTS:**  
Generally well tolerated.  
GI side effects (diarrhoea, vomiting, abdominal pain)  
Conjunctivitis  
Transient rise in transaminases  
Rare: anaphylaxis and severe skin reactions  

**COMMENTS:**  
The osmolality of a dispersed capsule is 75 mOsm/kg. The osmolality of the suspension will be greater than this, and is suitable for infants on full feeds only.  
The reconstituted suspension does NOT require refrigeration and should be discarded after 10 days.  
Discard any unused dispersed capsule immediately.  

**REFERENCES:**  
Neofax 2013  
Tamiflu® Product Information  
WA Department of Health “Operational Directives” OD0202/09, OD0203/09  

**DATE:** October 2013